Study for Ongoing Access and Long-Term Safety of Study Drugs
Sponsor: Daiichi Sankyo
ClinicalTrials ID:NCT06174987
This study allows participants who are benefiting from certain treatments in previous studies to continue receiving them. It also checks the long-term safety of these treatments.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is designed to let participants continue using treatments they found helpful in earlier studies sponsored by Daiichi Sankyo, Inc. or in collaboration with AstraZeneca. It will also monitor the long-term safety of these treatments. Participants will be part of a larger study that includes different treatments, each with its own specific guidelines.
Description
This study is a continuation for participants who have been part of previous studies and are benefiting from the treatments. It includes various sub-studies, each focusing on different treatments. The main goal is to ensure that participants can keep receiving the treatments that are helping them, while also keeping track of any long-term safety concerns. Participants will need to follow the guidelines set for each specific treatment they are receiving.
Eligibility Criteria
Inclusion Criteria
- Must have signed a consent form and agree to follow all study requirements.
- Currently participating in a previous study sponsored by Daiichi Sankyo or Daiichi Sankyo/AstraZeneca that has reached its end.
- Must not show any signs of the disease getting worse and must be benefiting from the treatment according to the study doctor.
Exclusion Criteria
- Participants with any ongoing side effects that require stopping the study drug.
- Participants who have stopped T-DXd therapy for more than 18 weeks (126 days) between the last dose in the previous study and starting this study.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.